Abstract
There is a trend of increasing prevalence of neuroendocrine tumors (NETs), and the inherited multiple endocrine neoplasia type 1 (MEN1) syndrome serves as a genetic model to investigate how NETs develop and the underlying mechanisms. Menin, encoded by the MEN1 gene, at least partly acts as a scaffold protein by interacting with multiple partners to regulate cellular homeostasis of various endocrine organs. Menin has multiple functions including regulation of several important signaling pathways by controlling gene transcription. Here, we focus on reviewing the recent progress in elucidating the key biochemical role of menin in epigenetic regulation of gene transcription and cell signaling, as well as posttranslational regulation of menin itself. In particular, we will review the progress in studying structural and functional interactions of menin with various histone modifiers and transcription factors such as MLL, PRMT5, SUV39H1 and other transcription factors including c-Myb and JunD. Moreover, the role of menin in regulating cell signaling pathways such as TGF-beta, Wnt and Hedgehog, as well as miRNA biogenesis and processing will be described. Further, the regulation of the MEN1 gene transcription, posttranslational modifications and stability of menin protein will be reviewed. These various modes of regulation by menin as well as regulation of menin by various biological factors broaden the view regarding how menin controls various biological processes in neuroendocrine organ homeostasis.
Introduction
In recent years, prevalence of neuroendocrine tumors is increasing (Jiao et al. 2011), and the multiple endocrine neoplasia type 1 (MEN1) gene, which encodes protein menin, is genetically well characterized for its function in regulating cell homeostasis in various endocrine organs including the pituitary, parathyroid glands and pancreatic islets. Various excellent reviews on the structure and functions of menin in regulating cell proliferation and tumor suppressing have been reported (Agarwal et al. 2005, Balogh et al. 2006, 2010, Yang & Hua 2007, Wu & Hua 2008, Matkar et al. 2013). Here, we mainly focus on reviewing the recent progress in the key biochemical role and the underlying mechanisms of menin in epigenetic regulation, as well as posttranslational regulation of menin itself.
Regulation of histone modifying enzymes by menin
Menin regulates MLL
It has been reported that menin interacts with mixed lineage leukemia 1 (MLL1) (Canaff et al. 2012a) and MLL2 (Hughes et al. 2004), both harbor a SET-domain that possess histone 3 lysine 4 (H3K4) methyltransferase. MLL1 was originally identified as a gene interrupted in chromosomal translocations responsible for the development of acute leukemia in adults (Marschalek 2011), with an even higher incidence in infant leukemia (Tomizawa et al. 2007). The MLL gene can fuse with one of over 60 partner genes via chromosomal translocation, leading to the formation of chimeric MLL fusion proteins. These fusion proteins retain an approximately 1400 amino acid N-terminal fragment. Expression of MLL fusion proteins enhances proliferation and blocks differentiation of hematopoietic cells, ultimately leading to acute leukemia (Slany 2005).
Crystallographic studies indicate that menin adopts a rectangular-shaped conformation that resembles a curved left hand, with a deep pocket formed by the thumb and the palm (Huang et al. 2012). Menin binds a short peptide from the N-terminus of MLL1 with a pocket structure. The part of MLL binding to menin is the N-terminus retained in all MLL fusions (Yokoyama et al. 2004, 2005). Menin forms a complex with MLL and several other cofactors including WDR5 and ASH2L, leading to histone 3 lysine 4 trimethylation (H3K4me3) at the promoter of the target genes (Hughes et al. 2004, Milne et al. 2005, Yokoyama et al. 2005, Chen et al. 2006, Caslini et al. 2007, Onodera et al. 2010, Thiel et al. 2010). For instance, in MLL fusion protein-induced leukemia cells, menin is required for the expression of certain homeotic genes, such as Hoxa9, Hoxc6 and Hoxc8 in concert with MLL1 (Hughes et al. 2004, Yokoyama et al. 2004). Targeted deletion of the Men1 gene reduces the binding of MLL1 to the Hoxa9 locus (Chen et al. 2006, Tomizawa et al. 2007). On the other hand, in endocrine cells or mouse embryonic fibroblasts (MEFs), menin is required for MLL1 binding to the cyclin-dependent kinase (CDK) inhibitors, p27Kip1 and p18Ink4c loci to increase H3K4me3 and induce their expression (Milne et al. 2005). Menin is also required for recruiting MLL1 to the GATA3 locus to regulate GATA3 expression and Th2 cytokine production in T helper type 2 (Th2) cells (Onodera et al. 2010). These studies all strongly suggested that menin plays an important role in recruiting MLL methyltransferase complex to the promoters of the target genes and increase their transcription.
Besides directly binding to the N-terminus of MLL1 via the central pocket, menin also directly binds chromatin-associating protein LEDGF (lens epithelium-derived growth factor) (Yokoyama & Cleary 2008, van Nuland et al. 2013). LEDGF is crucial for co-localization of menin and wild-type MLL1 or MLL fusions to the loci of menin/MLL target genes such as Hox and CDKIs (Yokoyama & Cleary 2008). Importantly, crystallographic studies indicate that menin, the N-terminal part of MLL, and LEDGF form a ternary complex in which a helical structure from LEDGF sits on a ‘V’ shape structure formed from a MLL helix and menin. This structure clearly shows that menin acts as a scaffold to recruit both MLL and LEDGF (Huang et al. 2012). Moreover, although menin has no DNA-binding domains, menin can associate with chromatin (Jin et al. 2003), and directly binds to genomic DNA via the positively charged amino acid residues in the nuclear localization signals (NLSs) of menin (La et al. 2006). These findings indicate that menin acts as a scaffold to recruit the MLL complex to its target genes partly via its binding to genomic DNA via the NLSs.
To broaden the view of menin binding to genomic DNA in an unbiased manner, genome-wide analysis shows that menin and MLL1 co-localize to the promoters of thousands of human genes, but they do not always bind together (Scacheri et al. 2006). In addition, menin and MLL could regulate distinct pathways separately in hematopoietic stem cells and developing B cells (Li et al. 2013). Nevertheless, targeted deletion or knockdown of the Men1 gene in various types of cells only affects the expression of several dozens of genes (Li et al. 2013), indicating that menin is not required for regulating the expression of all the genes it binds as shown in the chromatin immunoprecipitation (ChIP) assay. Consistent with this, menin is not absolutely required for MLL1-mediated normal hematopoiesis (Li et al. 2013), but is required for the maintenance of MLL fusion protein-induced leukemia cells (Bouffioux & Dusart 1974, Grembecka et al. 2012).
Menin regulates PRMT5
Menin also regulates protein arginine methyltransferase 5 (PRMT5) function (Gurung et al. 2013b), a member of PRMT family (Bedford & Clarke 2009, Stopa et al. 2015). Based on distinct catalytic effect on forming either asymmetric or symmetric dimethylation at arginine, PRMT family members are classified into either type 1 or type 2, accordingly. PRMT5 belongs to type 2 enzyme and works together with its cofactor MEP50 to mediate the methylation of histones H2A and H4 at arginine 3 and histone H3 at arginine 8 (Karkhanis et al. 2011). PRMT5 also has multiple non-chromatin protein substrates such as p53, p65 and HoxA9 (Le Guezennec et al. 2006, Jansson et al. 2008, Bandyopadhyay et al. 2012, Wei et al. 2013, Yang et al. 2014). In addition, PRMT5 can repress globin gene expression through recruitment of DNA methyltransferase 3A (DNMT3A), indicating a potential cross-talk between histone arginine methylation and DNA methylation (Zhao et al. 2009, Rank et al. 2010, Girardot et al. 2014). Posttranslational histone modifications catalyzed by PRMT5 significantly affect gene expression and regulate cell growth and proliferation (Scoumanne et al. 2009). Our previous data shows that menin directly binds to PRMT5 and target histone 4 arginine 3 symmetric dimethylation (H4R3me2s) at promoters of Gas1 and Gli1 to suppress Hedgehog (HH) signaling and proliferation of neuroendocrine cells (Gurung et al. 2013a,b).
Menin regulates PRMT5’s function by several modes. First, menin can suppress glucagon-like peptide-1 (GLP1)-induced and PKA-mediated phosphorylation of both FOXO1 and cyclic adenosine monophosphate (cAMP) response element-binding protein (CREB), likely through PRMT5 or PRMT5-like enzyme-mediated methylation of FOXO1 and CREB (Muhammad et al. 2017). Second, menin recruits PRMT5 to the promoter of the Gas1 gene, increases repressive H4R3me2s and suppresses Gas1 expression. Third, menin can also recruit PRMT5 to the promoter of Gli1 and subsequently repress Gli1 expression and thus Hedgehog signaling (Gurung et al. 2013a). However, further molecular details remain to be investigated.
Menin regulates SUV39H1 and Daxx
Menin has been reported to silence the transcription of target genes by interacting with the suppressor of variegation 3–9 homolog protein 1 (SUV39H1) and increasing the histone 3 lysine 9 trimethylation (H3K9me3) at the promoter of the target genes (Yang et al. 2013, Song et al. 2014, Feng et al. 2017). SUV39H1 is a histone 3 lysine 9 (H3K9) methyltransferase (Rea et al. 2000). Menin interacts with SUV39H1 through 360–445 amino acid region of menin and recruits SUV39H1 to the promoters of GBX2 and IL6 and represses their expression via enhancing H3K9me3 (Yang et al. 2013, Song et al. 2014). Recently, we found that menin directly binds to Daxx/ATRX complex and further recruits SUV39H1 to the promoter of membrane metallo-endopeptidase (Mme, or CD10) and represses Mme expression by enhancing H3K9me3 at the Mme promoter (Feng et al. 2017). Daxx is a H3.3-specific histone chaperone and deposits H3.3 at specific chromatin regions in cooperation with ATRX (Drane et al. 2010, Lewis et al. 2010) and frequently mutated in neuroendocrine tumors (Jiao et al. 2011). Menin and Daxx are required for each other to recruit SUV39H1 to the Mme promoter, and menin directly binds to Daxx through 396–450 amino acid region (Feng et al. 2017). Daxx also directly binds to ATRX, which may also bind SUV39H1-binding domain (Tang et al. 2004, Yang et al. 2013, Feng et al. 2017). These findings suggest that menin and Daxx/ATRX firstly form a complex and then recruit SUV39H1 to the Mme promoter and increase H3K9me3, leading to the suppression of Mme expression.
Crosstalk between menin and transcription factors
Several transcription factors have been reported to interact with menin. Some of them have been shown to be functionally important in their interaction.
JunD
Menin interacts with JunD and represses the JunD activity (Agarwal et al. 1999, Huang et al. 2012). JunD is a transcription factor belonging to the AP1 family and is involved in negative control of cell proliferation (Hernandez et al. 2008). The crystal structural study showed that menin binds JunD via its central pocket, which can also bind to the MLL1 peptide (Huang et al. 2012). In other words, menin uses the same pocket to bind either MLL1 or JunD. A conserved sequence (FPXXP) is found in the menin-binding domain (MBD) of both JunD and MLL (Huang et al. 2012). The region of JunD that binds menin spans 27–47 amino acid residues (Agarwal et al. 1999, Huang et al. 2012). Earlier biochemical studies have suggested that menin binds to JunD to repress JunD-induced transcription through interaction with co-repressors mSin3A and HDAC 1 or 2 in cultured cells (Agarwal et al. 1999, Gobl et al. 1999, Kim et al. 2003). Recently, we unraveled a new mechanism whereby menin binds JunD and thus block c-Jun N-terminal kinase (JNK)-mediated phosphorylation of JunD at residues S90, S100 and T117, an event crucial for activating JunD function in transcriptional regulation (Huang et al. 2012). Coincidently, both the basic residues and the leucine residues in JunD are bound by JNK to phosphorylate JunD, and these residues are also bound by menin. As such, menin binding to JunD effectively blocks JNK’s interaction with JunD and thus inhibits JNK-mediated phosphorylation and activation of JunD. This finding well explains why JunD activates proliferation of MEFs in the absence of menin, but suppresses proliferation in the presence of menin (Agarwal et al. 2003). In addition, JunD has two isoforms: full-length and truncated isoforms, and menin only can bind to full-length isoform of JunD (Yazgan & Pfarr 2001).
c-Myb and c-Myc
c-Myb binds and recruits menin to the promoters of Hox genes (Jin et al. 2010). c-Myb, GATA-3 and menin form a core transcription complex that promotes the expression of GATA-3 and Hox genes in leukemia cells. This complex also recruits MLL to promote Th2 cell maturation (Nakata et al. 2010). However, unlike regulation by menin/MLL-mediated H3K4me3 at the promoter (Jin et al. 2010) of the target genes, a recent report shows that menin can directly interact with the transactivation domain (TAD) of Myc and then bind to E-boxes to enhance transcription of Myc target genes (Wu et al. 2017). This enhanced transcription of MYC target genes depends on P-TEFb, a key factor to facilitate transcription regulation by MYC (Wu et al. 2017). The above findings indicate that, by transcriptionally promoting the expression of MYC target genes, menin can stimulate cell proliferation, cellular metabolism and cancer progression in certain types of cancers including MLL fusion protein-induced leukemia cells.
NF-κB
The NF-κB has several components including p50, p52 and p65 and found to interact specifically with menin in vitro and in vivo (Heppner et al. 2001). The binding region of NF-κB proteins with menin is at their N-terminal part. The interaction between menin and NF-κB represses PMA (phorbol 12-myristate 13-acetate)-stimulated or TNF-α-stimulated NF-κB activation in HeLa, Cos7 and NTERA-2 cells. p65 phosphorylation was dramatically increased by RET constitutive activation and was negatively correlated with menin expression in parathyroid neoplasia (Corbetta et al. 2005). In menin knockdown IEC-17 cells, a non-transformed crypt-like cell line, cyclin D1 expression is increased and the increased expression is partly due to the upregulation of NF-κB-mediated transcription (Theillaumas et al. 2008). These findings demonstrate a correlation among menin, NF-κB and cyclin D1 in regulating proliferation of the intestinal epithelial cells. However, it remains to be investigated whether menin and NF-κB are co-localized to the loci of their target genes to regulate gene expression or not. One study in hepatocellular carcinoma showed that menin could repress p65 acetylation through recruitment of Sirt1, an enzyme that deacetylases p65 in lysine 310 (K310) (Gang et al. 2013). In RPA2 high expression-dependent breast cancer cells, RPA2 decreases the binding level between menin and NF-kB in a competitive way and relieves the antagonistic function of menin on NF-κB-regulated transcription (Chen et al. 2017). These studies suggest that menin regulates gene transcription by directly modifying NF-κB pathway in certain types of cancer cells.
Menin regulates various signaling pathways
TGF-beta signaling pathway
Transforming growth factor beta (TGF-beta) superfamily proteins have many important biological functions, including regulation of tissue differentiation, cell proliferation and migration in both normal and cancer cells (Yokobori & Nishiyama 2017). Menin regulates TGF-beta signaling and TGF-beta-induced gene transcription by interacting with Smad3, a TGF-beta downstream effector (Kaji et al. 2001). Menin directly interacts with Smad3 and inhibit Smad3/4-DNA binding at specific transcriptional regulatory sites to regulate their expression (Kaji et al. 2001). When the Men1 gene is deleted in Leydig cells, the effect of TGF-beta-induced inhibition of proliferation was reduced (Hussein et al. 2008). Consistently, Canaff and coworkers showed that menin mutation compromises menin’s function in promoting TGF-beta-induced Smad3 transcriptional activity (Canaff et al. 2012a). Thus, menin mutation deprives its function in promoting TGF-beta signaling-induced repression of cell proliferation, likely contributing to the development of MEN1. On the other hand, it is also reported that TGF-beta upregulates menin expression in MLL-AF9-transformed mouse bone marrow cells (Zhang et al. 2011). Moreover, menin expression was downregulated in MLL-AF9-transformed mouse bone marrow cells when TβRII, a vital component in TGF-beta signaling pathway, was deleted. Menin expression was also decreased in liver samples from the conditional TβRII-knockout mice after TβRII excision (Zhang et al. 2011).
Wnt signaling
Menin was shown to be crucial for regulating canonical Wnt/β-catenin signaling in cultured rodent islet tumor cells by interaction with β-catenin (Chen et al. 2008). In Men1-null MEFs and insulinomas from β-cell-specific Men1-knockout mice, β-catenin accumulates in the nucleus, but overexpression of menin reduces nuclear accumulation of β-catenin and suppresses its transcriptional activity (Cao et al. 2009). Wnt signaling stimulates pancreatic islet β cell proliferation, possibly by increasing expression of paired-like homeodomain 2 (Pitx2) (Rulifson et al. 2007). When menin and activated β-catenin are overexpressed in islet tumor cells, the Wnt/β-catenin downstream target gene, Axin2, is significantly enhanced, correlating with increased H3K4me3 at the promoter of the Axin2 gene (Chen et al. 2008). It is possible that menin promotes Wnt signaling in late stage of islet tumor development or inhibits Wnt signaling to prevent β cells from tumorigenesis at the early stage. These opposite results for the role of menin on the Wnt signaling pathway and cell proliferation may depend on distinct context of cells.
Beta cell-specific conditional knockout of β-catenin in Men1-deficient mice leads to suppression of tumorigenesis and significantly improved hypoglycemia and the survival rate of the mice (Jiang et al. 2014). Antagonizing β-catenin signaling by the small molecule inhibitor PKF115–584 in Men1-deficient mice also suppresses tumor cell proliferation in vitro and in vivo (Jiang et al. 2014). These findings suggest that suppression of β-catenin signaling inhibits the expression of pro-proliferative genes in Men1-null islets and improves hyperinsulinemia and hypoglycemia in the mice.
Hedgehog signaling
In pancreatic ductal adenocarcinoma, menin expression was suppressed by DNA methyltransferase 1 (DNMT1) downstream of the Hedgehog signaling pathway, and menin overexpression strongly antagonized the promotion effect of Hedgehog signaling on pancreatic cancer cell proliferation (Cheng et al. 2016). Aberrant activity of the Hedgehog signaling pathway has been reported in many types of cancers including basal cell carcinoma (BCC) (Xie et al. 1998) and medulloblastoma (Thompson et al. 2006). Moreover, the expression of Hedgehog ligand is enhanced in human gastrointestinal neuroendocrine tumors and in mouse small-cell lung cancer (Shida et al. 2006, Park et al. 2011). In genetically engineered mouse models of pancreatic ductal adenocarcinoma (PDAC), inhibition of Hedgehog signaling results in the depletion of the stroma surrounding the tumor, stimulating angiogenesis and enhancing delivery of chemotherapeutic drugs to inhibit the cancer cells (Olive et al. 2009).
It is suggested that the Hedgehog/DNMT1/menin axis is a potential molecular target for pancreatic cancer therapy (Cheng et al. 2016). Our previous study indicated that menin antagonizes Hedgehog signaling, partly via increasing PRMT5-mediated repressive H4R3me2s at the Gas1 promoter in neuroendocrine cells (Gurung et al. 2013b). Men1-null cells complemented with menin mutants fail to repress Gas1 mRNA levels, but the wild type did so (Gurung et al. 2013b). Moreover, menin and PRMT5 also suppress Hedgehog signaling at a second step besides Gas1, by inhibiting the expression of Hedgehog downstream effector Gli1. These findings indicate that loss of menin-mediated repressive histone methylation, H4R3me2s, at the Gas1 and Gli1 promoters and resulting upregulation of Hedgehog signaling play a role, at least in part, toward pathogenesis of the MEN1 syndrome.
Menin and PI3K/AKT signaling
Heterozygous Men1-knockout mice developed insulinoma (Crabtree et al. 2001, Bertolino et al. 2003) and Men1 excision increased proliferation of β cells and islet size (Yang et al. 2010a,b), indicating that menin is crucial for regulating β cells. Menin expression was reduced in high glucose-stimulated INS1 insulinoma cells and primary rat islets (Zhang et al. 2012). PI3K/AKT inhibitors suppress glucose-induced repression of menin expression (Zhang et al. 2012). A major downstream target of the PI3K/AKT pathway, FOXO1, promotes menin expression in INS1 cells by binding to the promoter of menin (Wang et al. 2011, Zhang et al. 2012). Activated AKT can phosphorylate FOXO1 and decline its transcription activity (Martinez et al. 2006), further to downregulate menin expression.
Menin regulates pancreatic islet alpha cell to beta cell differentiation
Menin is also a crucial factor inhibiting pancreatic islet alpha cell trans-differentiation into beta cell lineage. Mice with alpha cell-specific knockout of the Men1 gene developed insulin-secreting beta cell tumors or insulinomas 6 months following the Men1 deletion (Lu et al. 2010). Genetic cell lineage tracing analysis showed that insulinoma cells were directly derived from transdifferentiating glucagon-expressing cells (Lu et al. 2010). It remains to be investigated as to what pathway(s) is perturbed or the epigenetic reprogramming altered in the Men1-deleted alpha cells, resulting in alpha cell to beta cell trans-differentiation.
Regulation of GI-NETs by menin
As a tumor suppressor, menin epigenetically inhibits proliferation of neuroendocrine tumors via several different pathways, such as binding of menin to PRMT5 and enhancing H4R3me2s at promoters of Gas1 and Gli1 to suppress Hedgehog signaling (Gurung et al. 2013a,b), and menin also recruits Daxx/ATRX and SUV39H1 to Mme promoter and represses Mme expression by increasing H3K9me3 level (Feng et al. 2017). Neuroendocrine tumors have several different types, such as gastrointestinal neuroendocrine tumors (GI-NETs), which are the most frequent type as about 75% of these tumors have stimulation of gastrin. GI tract NETs are usually associated with MEN1 or Zollinger–Ellison syndrome (ZES), especially in the duodenum or stomach. 23% of the GI-NETs are gastric carcinoids (Burkitt & Pritchard 2006), the incidence of which has been increased in recent years. Type 2 gastric carcinoids comprise 5–8% of all the gastric carcinoids. 16% of duodenal gastrinomas have the mutations in the MEN1 gene and these tumors developed type 2 gastric carcinoids (Anlauf et al. 2005). Merchant group reported that Men1 deletion in the gastrointestinal mucosa induces hypergastrinemia and epithelial hyperplasia, but no tumors developed (Veniaminova et al. 2012). However, their further study showed that mice with double conditional knockout of Men1 and somatostatin genes developed gastric carcinoids (Sundaresan et al. 2017). They also found that the developed gastric carcinoids are correlated with nuclear export of p27 and the human gastric carcinoids have the p27 protein loss. The loss of p27 protein is possible due to the phosphorylation-induced degradation. On the other hand, menin recruits MLL to the promoters of p27Kip1 and p18Ink4c and increases their expression by enhancing the H3K4me3 (Milne et al. 2005). Therefore, the reduced p27 protein level may be also partly due to the inactivating mutations of MEN1 gene.
Menin and K-Ras signaling regulate each other
Menin suppresses both proliferation and migration of lung adenocarcinoma cells partly via inhibiting PTN and its receptor RPTP β/ζ signaling (Gao et al. 2009, Feng et al. 2010). However, menin also is repressed by K-Ras through DNMT1-dependent DNA demethylation of the promoter of the MEN1 gene in lung adenocarcinoma cells and inversely menin reduces the level of active Ras-GTP at least partly by preventing GRB2 and SOS1 from binding to Ras (Wu et al. 2012); these studies suggest a potential negative feedback loop between menin and K-Ras, and menin plays a crucial role in K-Ras-induced lung cancer development.
Menin and miRNAs
miRNA biogenesis
We previously found that menin interacts with arsenite-resistant protein 2 (ARS2), a component of the nuclear RNA CAP-binding complex that is crucial for biogenesis of certain miRNAs including let-7a (Gurung et al. 2014). Menin does not affect the levels of primary-let-7a (pri-let-7a), but increases the levels of mature let-7a (Gurung et al. 2014). Let-7a targets, including insulin receptor (INSR) and insulin receptor substrate 2 (IRS2), pro-proliferative genes that are crucial for insulin-mediated signaling, are upregulated in Men1-excised cells (Gurung et al. 2014). Inhibition of let-7a using anti-miRNA in wild-type cells is sufficient to enhance the expression of IRS2. Depletion of menin inhibits conversion of pri-miRNA to pre-miRNA. Knockdown of ARS2 in menin-expressing cells repressed let-7a processing. However, ARS2 knockdown had little impact on let-7a expression in menin-deleted cells. These findings unravel a mechanism whereby menin suppresses cell proliferation, at least partly by promoting the biogenesis and processing of certain miRNAs, including let-7a, to insulin signaling and likely endocrine cell proliferation.
Other miRNA processing
miR-24-1 directly binds to the highly conserved 3′UTR region of MEN1 mRNA and represses menin expression, and the negative feedback loop between miR-24-1 and menin protein is essential for MEN1 tumorigenesis (Luzi et al. 2012). Vijayaraghavan and coworkers also found that miR-24 directly decreases menin expression and impacts downstream cell cycle inhibitors in neuroendocrine tumors (Vijayaraghavan et al. 2014). Moreover, miR-24 inhibition increases menin expression and decreases cholangiocarcinoma cell proliferation (Ehrlich et al. 2017). Except for miR-24, several other miRNAs have been found to have the ability to repress menin expression in various tissues. Overexpression of miR-421 represses menin expression and enhanced cell proliferation and invasion of neuroblastoma cells (Li et al. 2014). Ectopic expression of miR-29b precursor reduced, but inhibition of miR-29b increased the mRNA and protein levels of menin (Ouyang et al. 2015). miR-17 induced by glucose inhibits menin expression by targeting its 3′-untranslated region and promotes pancreatic β cell proliferation (Lu et al. 2015). More recent findings showed that expression levels of miR-762 and menin in ovarian cancer tissues are correlated, and miR-762 downregulates menin expression through a binding site in the 3′UTR region, and further increases the Wnt signaling pathway to promote ovarian cancer (Hou et al. 2017). Taken together, menin expression can be repressed by multiple distinct miRNAs at posttranscriptional level, while menin also can regulate expression of some miRNAs.
Regulation of menin transcriptional expression
Regulation of menin expression by prolactin signaling
As menin plays an important and pleiotropic role in regulating multiple functions of islets, it is conceivable that its expression is controlled by numerous signals. During late stage of pregnancy of mice, prolactin is produced, and prolactin binds its cell surface receptor and phosphorylates and activates STAT1 (Tourkine et al. 1995, Jabbour et al. 1998, Karnik et al. 2007). The activated STAT1 translocates into the nuclear beta cells, and then binds to the promoter of the Men1 gene, to suppress transcription of the Men1 gene (Karnik et al. 2007). Notably, controlled expression of the Men1 transgene in the pancreatic islets attenuates the prolactin-induced repression of the Men1 expression in the pancreatic islets, leading to gestational diabetes in the mice (Karnik et al. 2007). These findings indicate that menin is physiologically regulated to adapt the pancreatic islets to counteract the development of gestational diabetes. More work remains to investigate whether this molecular circuitry is also conserved in human pancreatic islets.
Regulation by FOXO1
While menin is repressed by the prolactin signaling pathway (Karnik et al. 2007), menin expression is activated by FOXO1 (Zhang et al. 2012), which is a member of Forkhead box-containing transcription factor family (Anderson et al. 1998). A key feature of this family of transcription factors is that many of them can be phosphorylated by receptor tyrosine kinases (RTK) by activating PI3K/AKT pathway (Brunet et al. 1999). AKT can phosphorylate FOXO1 at three distinct sites, Thr24, Ser256 and Ser319. For instance, insulin induces FOXO1 phosphorylation by activating PI3K and AKT axis, and the phosphorylated FOXO1 binds to 14-3-3 protein and is sequestered in the cytoplasm (Tzivion et al. 2011). Moreover, the phosphorylated FOXO1 in the nucleus can also be exported into the cytoplasm. Thus, the net outcome of phosphorylation of FOXO1 is to reduce its nuclear localization and thus its activity in transcriptional activation (Vogt et al. 2005). Further, the phosphorylated FOXO1 is also channeled for ubiquitin-dependent protein degradation (Matsuzaki et al. 2003, Aoki et al. 2004). It is clear that FOXO1 is crucial for regulating insulin signaling and also cell metabolism (Kitamura 2013). As such, it is quite interesting to note that glucose induces activation of AKT (Zhang et al. 2012) and suppresses FOXO1 activity. Activation of FOXO1 upon reducing phosphorylation leads to increased menin expression. Therefore, menin regulation is linked to an important signaling pathway regulating beta cell, metabolism and diabetes.
Somatostatin increases menin expression
Somatostatin is a peptide hormone and inhibitor of gastrin expression and secretion. Menin also inhibits the expression of gastrin. Somatostatin analog octreotide increases the mRNA and protein levels of menin in the duodenum of mice. While octreotide inhibited PKA enzyme activity and forskolin treatment, which increases cellular cAMP and PKA activity, suppressed menin protein level (Mensah-Osman et al. 2008). However, whether and how the somatostatin pathway regulates PKA to induce the expression of menin remains to be elucidated.
Regulation of menin by posttranslational modifications
Posttranslational modifications (PTMs), also known as protein level regulation, play a crucial role for regulating protein functions and thus cellular processes and various biological activities such as transcriptional regulation and cell signaling (Orford et al. 1997, Waby et al. 2008). Currently, multiple PTMs have been found for various proteins, including phosphorylation, methylation, acetylation, ubiquitination, myristylation, nitration, glycosylation and SUMOylation (Ribet & Cossart 2010). For instance, tumor suppressor and transcription factor p53 undergoes extensive posttranslational modifications, such as ubiquitination, methylation, SUMOylation and phosphorylation to regulate its variety of biological activities (Stehmeier & Muller 2009, Brooks & Gu 2011, Meek 2015). Recently, menin has been found to be regulated by various PTMs including ubiquitination, SUMOylation, phosphorylation and palmitoylation (He et al. 2016). However, the biological and functional impact of these PTMs on menin remains to be further investigated.
Ubiquitination
The first posttranslational modification of menin was found to be ubiquitination in 2004 by Naganari Ohkura group (Yaguchi et al. 2004). They found that MEN1-derived missense mutant menin protein has much short half-life as compared to wild-type menin protein in transfected 293 cells. Further studies reveal that the reduced levels of the mutant proteins were a result of rapid menin degradation through ubiquitin-mediated degradation. The unstable menin mutants, but not wild-type menin, were associated with a heat shock protein Hsp70 and its co-chaperone CHIP, which was shown to function as a ubiquitin E3 ligase toward several substrates presented by Hsp70 and Hsp90 (Connell et al. 2001, Meacham et al. 2001). Ubiquitination of menin missense mutants were also reported by Hendy group, and they showed that reduction of either Hsp70 or CHIP expression by siRNA-mediated knockdown stabilizes the menin missense mutants, indicating that CHIP is the E3 ubiquitin ligase of menin mutants presented by Hsp70 for proteasome-mediated degradation (Canaff et al. 2012b). These findings are consistent with the observation that menin protein level is reduced in MEN1-mutated neuroendocrine tumors. While a much longer period (12 h) of treatment with MG132, a proteasome inhibitor, prevented the reduction of the amount of wild-type menin protein (Yaguchi et al. 2004); whether the wild-type menin is subjected to ubiquitin-mediated degradation in normal cells, or in what type of cells, remains unclear.
SUMOylation
Another type of PTMs involves attachment of the small ubiquitin-related modifier (SUMO), originally reported as a protein related to ubiquitin, to protein substrates, and this process is referred to as SUMOylation (Bayer et al. 1998, Geiss-Friedlander & Melchior 2007). SUMOylation has been shown to be important in regulating many cell processes including transcription, replication, chromosome segregation and DNA repair (Johnson 2004, Geiss-Friedlander & Melchior 2007). We found that menin undergoes SUMO modification and Lys591 is one of the SUMOylation sites (Feng et al. 2013). Full-length menin with L591R mutation can still be SUMOylated, suggesting that multiple SUMOylation sites exist and the menin SUMOylation site (QKVS) is not consistent with the consensus SUMO-interacted motif, which implies the possible existence of a menin-specific E3 ligase (Melchior et al. 2003). However, thus far, no functional effect of SUMOylation on menin has been observed.
Phosphorylation
The first phosphorylation modification of menin was found in 2006 by Matthew Meyerson group (MacConaill et al. 2006). Protein phosphorylation is considered to be the most abundant posttranslational modification in eukaryotes. They initially found that menin migrated as a doublet on SDS-PAGE gels, indicating a possible posttranslational modification (Hughes et al. 2004). Further study showed that menin is phosphorylated on two serine residues, Ser543 and Ser583 (MacConaill et al. 2006). However, the functional study of the phosphorylation by mutating both serine residues had no impact on menin’s ability to recruit trithorax family complex proteins Ash2L, Rbbp5 and MLL2, nor on cell proliferation (MacConaill et al. 2006). While these two phosphorylation sites are situated between the two NLSs located at the C-terminal part of menin, mutations at both of the serine residues do not affect menin localization into the nucleus (MacConaill et al. 2006). Additional phosphorylation sites of menin, Ser394 and Ser487, were also identified by mass spectrometry analysis (Francis et al. 2011). Phosphorylation of menin at Ser394 was induced in response to irradiation (IR) or UV treatment (Francis et al. 2011), while Ser487 was phosphorylated under normal cell culture conditions. Nonetheless, HMT activity assay showed both Ser394 and Ser487-mutated menin mutant was still able to immunoprecipitate methylated histone 3. Several phosphorylation sites of menin have been found, but the overall functional significance of menin phosphorylation is still unclear. Phosphorylation can be mediated by a plethora of protein kinases, and one possible way to elucidate the function of menin phosphorylation is to identify the cognate protein kinases and then evaluate the role of menin phosphorylation under relevant conditions.
Perspective
Physiological or pathological regulation of menin modifications and functions
Thus far, while multiple posttranslational modifications of menin have been reported, no clear biological functions attributed to the modifications have been unequivocally demonstrated. It is well documented that menin is phosphorylated in several residues, including the phosphorylation at Ser394 in response to several forms of DNA damage (Francis et al. 2011). However, so far it is unclear whether this phosphorylation has any consequence on menin function. Mutation of serine to alanine at the phosphorylation site did not affect cell cycle and cell proliferation (Francis et al. 2011). Moreover, it is also not clear whether SUMOylation of the menin affects its function in regulating homeostasis of the endocrine organs. Going forward, it is important to investigate the potential role of menin modifications on its biological functions and also crucial to uncover new layers of regulation of normal menin and its functional consequences.
Crosstalk between menin and GLP-1 pathway
It has been recently reported that menin represses expression of GLP-1 receptor (GLP1R), likely via interacting with protein arginine methyltransferases including PRMT5 (Muhammad et al. 2017). The precise mechanisms remain to be further investigated, and it is also crucial to understand whether GLP-1 pathway has any interplay with the menin function.
Interplay between the menin pathway and FOXO1 or CREB?
GLP-1 signaling and PKA induce phosphorylation of FOXO1 at the site which is also phosphorylated by insulin pathway-activated AKT (Muhammad et al. 2017). Notably, menin suppresses GLP-1-mediated phosphorylation of FOXO1. It is tantalizing to postulate that menin-PRMT5 can methylate the arginine residues close to the PKA phosphorylation site of FOXO1, but thus far, a direct PRMT5-mediated arginine methylation of the site was not demonstrated. Thus, it is important to find out whether/what arginine methyltransferase(s) may be responsible for the menin-mediated suppression of the FOXO1 phosphorylation. On the other hand, menin also inhibits GLP-1-mediated, PKA-dependent phosphorylation and thus activation of CREB, and it is important to elucidate how menin does so. It is also important to understand how menin coordinately suppresses a pro-beta cell factor CREB; yet suppresses a negative beta cell factor FOXO1, both via phosphorylation, as these studies will likely unravel the key role and underlying mechanism of menin in regulating islet homeostasis and likely diabetes, by uncovering the underlying mechanism.
Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.
Funding
This work was supported in part by grants from the NIH (1-R01-CA-178856 and R01 DK097555), AACR-Neuroendocrine tumor research foundation (NETRF) and Harrington Discovery Institute Innovator Scholar award.
References
Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, Saggar S, Chandrasekharappa SC, Collins FS & Spiegel AM et al. 1999 Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 96 143–152. (doi:10.1016/S0092-8674(00)80967-8)
Agarwal SK, Novotny EA, Crabtree JS, Weitzman JB, Yaniv M, Burns AL, Chandrasekharappa SC, Collins FS, Spiegel AM & Marx SJ 2003 Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. PNAS 100 10770–10775. (doi:10.1073/pnas.1834524100)
Agarwal SK, Kennedy PA, Scacheri PC, Novotny EA, Hickman AB, Cerrato A, Rice TS, Moore JB, Rao S & Ji Y et al. 2005 Menin molecular interactions: insights into normal functions and tumorigenesis. Hormone and Metabolic Research 37 369–374. (doi:10.1055/s-2005-870139)
Anderson MJ, Viars CS, Czekay S, Cavenee WK & Arden KC 1998 Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. Genomics 47 187–199. (doi:10.1006/geno.1997.5122)
Anlauf M, Perren A, Meyer CL, Schmid S, Saremaslani P, Kruse ML, Weihe E, Komminoth P, Heitz PU & Kloppel G 2005 Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas. Gastroenterology 128 1187–1198. (doi:10.1053/j.gastro.2005.01.058)
Aoki M, Jiang H & Vogt PK 2004 Proteasomal degradation of the FoxO1 transcriptional regulator in cells transformed by the P3k and Akt oncoproteins. PNAS 101 13613–13617. (doi:10.1073/pnas.0405454101)
Balogh K, Racz K, Patocs A & Hunyady L 2006 Menin and its interacting proteins: elucidation of menin function. Trends in Endocrinology and Metabolism 17 357–364. (doi:10.1016/j.tem.2006.09.004)
Balogh K, Patocs A, Hunyady L & Racz K 2010 Menin dynamics and functional insight: take your partners. Molecular and Cellular Endocrinology 326 80–84. (doi:10.1016/j.mce.2010.04.011)
Bandyopadhyay S, Harris DP, Adams GN, Lause GE, McHugh A, Tillmaand EG, Money A, Willard B, Fox PL & Dicorleto PE 2012 HOXA9 methylation by PRMT5 is essential for endothelial cell expression of leukocyte adhesion molecules. Molecular and Cellular Biology 32 1202–1213. (doi:10.1128/MCB.05977-11)
Bayer P, Arndt A, Metzger S, Mahajan R, Melchior F, Jaenicke R & Becker J 1998 Structure determination of the small ubiquitin-related modifier SUMO-1. Journal of Molecular Biology 280 275–286. (doi:10.1006/jmbi.1998.1839)
Bedford MT & Clarke SG 2009 Protein arginine methylation in mammals: who, what, and why. Molecular Cell 33 1–13. (doi:10.1016/j.molcel.2008.12.013)
Bertolino P, Tong WM, Herrera PL, Casse H, Zhang CX & Wang ZQ 2003 Pancreatic beta-cell-specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice. Cancer Research 63 4836–4841.
Bouffioux C & Dusart Y 1974 Proceedings: long-term results of surgical treatment of hydronephrosis. Acta Urologica Belgica 42 71–75.
Brooks CL & Gu W 2011 p53 regulation by ubiquitin. FEBS Letters 585 2803–2809. (doi:10.1016/j.febslet.2011.05.022)
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J & Greenberg ME 1999 Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 857–868. (doi:10.1016/S0092-8674(00)80595-4)
Burkitt MD & Pritchard DM 2006 Review article: pathogenesis and management of gastric carcinoid tumours. Alimentary Pharmacology and Therapeutics 24 1305–1320. (doi:10.1111/j.1365-2036.2006.03130.x)
Canaff L, Vanbellinghen JF, Kaji H, Goltzman D & Hendy GN 2012a Impaired transforming growth factor-beta (TGF-beta) transcriptional activity and cell proliferation control of a menin in-frame deletion mutant associated with multiple endocrine neoplasia type 1 (MEN1). Journal of Biological Chemistry 287 8584–8597. (doi:10.1074/jbc.M112.341958)
Canaff L, Vanbellinghen JF, Kanazawa I, Kwak H, Garfield N, Vautour L & Hendy GN 2012b Menin missense mutants encoded by the MEN1 gene that are targeted to the proteasome: restoration of expression and activity by CHIP siRNA. Journal of Clinical Endocrinology and Metabolism 97 E282–E291. (doi:10.1210/jc.2011-0241)
Cao Y, Liu R, Jiang X, Lu J, Jiang J, Zhang C, Li X & Ning G 2009 Nuclear-cytoplasmic shuttling of menin regulates nuclear translocation of {beta}-catenin. Molecular and Cellular Biology 29 5477–5487. (doi:10.1128/MCB.00335-09)
Caslini C, Yang Z, El-Osta M, Milne TA, Slany RK & Hess JL 2007 Interaction of MLL amino terminal sequences with menin is required for transformation. Cancer Research 67 7275–7283. (doi:10.1158/0008-5472.CAN-06-2369)
Chen YX, Yan J, Keeshan K, Tubbs AT, Wang H, Silva A, Brown EJ, Hess JL, Pear WS & Hua X 2006 The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression. PNAS 103 1018–1023. (doi:10.1073/pnas.0510347103)
Chen G, A J, Wang M, Farley S, Lee LY, Lee LC & Sawicki MP 2008 Menin promotes the Wnt signaling pathway in pancreatic endocrine cells. Molecular Cancer Research 6 1894–1907. (doi:10.1158/1541-7786.MCR-07-2206)
Chen CC, Juan CW, Chen KY, Chang YC, Lee JC & Chang MC 2017 Upregulation of RPA2 promotes NF-kappaB activation in breast cancer by relieving the antagonistic function of menin on NF-kappaB-regulated transcription. Carcinogenesis 38 196–206. (doi:10.1093/carcin/bgw123)
Cheng P, Wang YF, Li G, Yang SS, Liu C, Hu H, Jin G & Hu XG 2016 Interplay between menin and Dnmt1 reversibly regulates pancreatic cancer cell growth downstream of the Hedgehog signaling pathway. Cancer Letters 370 136–144. (doi:10.1016/j.canlet.2015.09.019)
Connell P, Ballinger CA, Jiang J, Wu Y, Thompson LJ, Hohfeld J & Patterson C 2001 The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nature Cell Biology 3 93–96. (doi:10.1038/35050618)
Corbetta S, Vicentini L, Ferrero S, Lania A, Mantovani G, Cordella D, Beck-Peccoz P & Spada A 2005 Activity and function of the nuclear factor kappaB pathway in human parathyroid tumors. Endocrine-Related Cancer 12 929–937. (doi:10.1677/erc.1.00970)
Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA, Lorang D, Libutti SK, Chandrasekharappa SC & Marx SJ et al. 2001 A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. PNAS 98 1118–1123.
Drane P, Ouararhni K, Depaux A, Shuaib M & Hamiche A 2010 The death-associated protein DAXX is a novel histone chaperone involved in the replication-independent deposition of H3.3. Genes and Development 24 1253–1265. (doi:10.1101/gad.566910)
Ehrlich L, Hall C, Venter J, Dostal D, Bernuzzi F, Invernizzi P, Meng F, Trzeciakowski JP, Zhou T & Standeford H et al. 2017 miR-24 inhibition increases menin expression and decreases cholangiocarcinoma proliferation. American Journal of Pathology 187 570–580. (doi:10.1016/j.ajpath.2016.10.021)
Feng ZJ, Gao SB, Wu Y, Xu XF, Hua X & Jin GH 2010 Lung cancer cell migration is regulated via repressing growth factor PTN/RPTP beta/zeta signaling by menin. Oncogene 29 5416–5426. (doi:10.1038/onc.2010.282)
Feng ZJ, Gurung B, Jin GH, Yang XL & Hua XX 2013 SUMO modification of menin. American Journal of Cancer Research 3 96–106.
Feng Z, Wang L, Sun Y, Jiang Z, Domsic J, An C, Xing B, Tian J, Liu X & Metz DC et al. 2017 Menin and Daxx interact to suppress neuroendocrine tumors through epigenetic control of the membrane metallo-endopeptidase. Cancer Research 77 401–411. (doi:10.1158/0008-5472.CAN-16-1567)
Francis J, Lin W, Rozenblatt-Rosen O & Meyerson M 2011 The menin tumor suppressor protein is phosphorylated in response to DNA damage. PLoS ONE 6 e16119. (doi:10.1371/journal.pone.0016119)
Gang D, Hongwei H, Hedai L, Ming Z, Qian H & Zhijun L 2013 The tumor suppressor protein menin inhibits NF-kappaB-mediated transactivation through recruitment of Sirt1 in hepatocellular carcinoma. Molecular Biology Reports 40 2461–2466. (doi:10.1007/s11033-012-2326-0)
Gao SB, Feng ZJ, Xu B, Wu Y, Yin P, Yang Y, Hua X & Jin GH 2009 Suppression of lung adenocarcinoma through menin and polycomb gene-mediated repression of growth factor pleiotrophin. Oncogene 28 4095–4104. (doi:10.1038/onc.2009.273)
Geiss-Friedlander R & Melchior F 2007 Concepts in sumoylation: a decade on. Nature Reviews: Molecular Cell Biology 8 947–956. (doi:10.1038/nrm2293)
Girardot M, Hirasawa R, Kacem S, Fritsch L, Pontis J, Kota SK, Filipponi D, Fabbrizio E, Sardet C & Lohmann F et al. 2014 PRMT5-mediated histone H4 arginine-3 symmetrical dimethylation marks chromatin at G + C-rich regions of the mouse genome. Nucleic Acids Research 42 235–248. (doi:10.1093/nar/gkt884)
Gobl AE, Berg M, Lopez-Egido JR, Oberg K, Skogseid B & Westin G 1999 Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism. Biochimica et Biophysica Acta 1447 51–56. (doi:10.1016/S0167-4781(99)00132-3)
Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ, Showalter HD, Murai MJ, Belcher AM & Hartley T et al. 2012 Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nature Chemical Biology 8 277–284. (doi:10.1038/nchembio.773)
Gurung B, Feng Z & Hua X 2013a Menin directly represses Gli1 expression independent of canonical Hedgehog signaling. Molecular Cancer Research 11 1215–1222. (doi:10.1158/1541-7786.MCR-13-0170)
Gurung B, Feng Z, Iwamoto DV, Thiel A, Jin G, Fan CM, Ng JM, Curran T & Hua X 2013b Menin epigenetically represses Hedgehog signaling in MEN1 tumor syndrome. Cancer Research 73 2650–2658. (doi:10.1158/0008-5472.CAN-12-3158)
Gurung B, Muhammad AB & Hua X 2014 Menin is required for optimal processing of the microRNA let-7a. Journal of Biological Chemistry 289 9902–9908. (doi:10.1074/jbc.M113.520692)
He X, Wang L, Yan J, Yuan C, Witze ES & Hua X 2016 Menin localization in cell membrane compartment. Cancer Biology and Therapy 17 114–122. (doi:10.1080/15384047.2015.1108497)
Heppner C, Bilimoria KY, Agarwal SK, Kester M, Whitty LJ, Guru SC, Chandrasekharappa SC, Collins FS, Spiegel AM & Marx SJ et al. 2001 The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene 20 4917–4925. (doi:10.1038/sj.onc.1204529)
Hernandez JM, Floyd DH, Weilbaecher KN, Green PL & Boris-Lawrie K 2008 Multiple facets of junD gene expression are atypical among AP-1 family members. Oncogene 27 4757–4767. (doi:10.1038/onc.2008.120)
Hou R, Yang Z, Wang S, Chu D, Liu Q, Liu J & Jiang L 2017 miR-762 can negatively regulate menin in ovarian cancer. OncoTargets and Therapy 10 2127–2137. (doi:10.2147/OTT.S127872)
Huang J, Gurung B, Wan B, Matkar S, Veniaminova NA, Wan K, Merchant JL, Hua X & Lei M 2012 The same pocket in menin binds both MLL and JUND but has opposite effects on transcription. Nature 482 542–546. (doi:10.1038/nature10806)
Hughes CM, Rozenblatt-Rosen O, Milne TA, Copeland TD, Levine SS, Lee JC, Hayes DN, Shanmugam KS, Bhattacharjee A & Biondi CA et al. 2004 Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Molecular Cell 13 587–597. (doi:10.1016/S1097-2765(04)00081-4)
Hussein N, Lu J, Casse H, Fontaniere S, Morera AM, Guittot SM, Calender A, Di Clemente N & Zhang CX 2008 Deregulation of anti-Mullerian hormone/BMP and transforming growth factor-beta pathways in Leydig cell lesions developed in male heterozygous multiple endocrine neoplasia type 1 mutant mice. Endocrine-Related Cancer 15 217–227. (doi:10.1677/ERC-06-0046)
Jabbour HN, Critchley HO & Boddy SC 1998 Expression of functional prolactin receptors in nonpregnant human endometrium: janus kinase-2, signal transducer and activator of transcription-1 (STAT1), and STAT5 proteins are phosphorylated after stimulation with prolactin. Journal of Clinical Endocrinology and Metabolism 83 2545–2553. (doi:10.1210/jcem.83.7.4989)
Jansson M, Durant ST, Cho EC, Sheahan S, Edelmann M, Kessler B & La Thangue NB 2008 Arginine methylation regulates the p53 response. Nature Cell Biology 10 1431–1439. (doi:10.1038/ncb1802)
Jiang X, Cao Y, Li F, Su Y, Li Y, Peng Y, Cheng Y, Zhang C, Wang W & Ning G 2014 Targeting beta-catenin signaling for therapeutic intervention in MEN1-deficient pancreatic neuroendocrine tumours. Nature Communications 5 5809. (doi:10.1038/ncomms6809)
Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL & Choti MA et al. 2011 DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331 1199–1203. (doi:10.1126/science.1200609)
Jin S, Mao H, Schnepp RW, Sykes SM, Silva AC, D’Andrea AD & Hua X 2003 Menin associates with FANCD2, a protein involved in repair of DNA damage. Cancer Research 63 4204–4210.
Jin S, Zhao H, Yi Y, Nakata Y, Kalota A & Gewirtz AM 2010 c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis. Journal of Clinical Investigation 120 593–606. (doi:10.1172/JCI38030)
Johnson ES 2004 Protein modification by SUMO. Annual Review of Biochemistry 73 355–382. (doi:10.1146/annurev.biochem.73.011303.074118)
Kaji H, Canaff L, Lebrun JJ, Goltzman D & Hendy GN 2001 Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. PNAS 98 3837–3842. (doi:10.1073/pnas.061358098)
Karkhanis V, Hu YJ, Baiocchi RA, Imbalzano AN & Sif S 2011 Versatility of PRMT5-induced methylation in growth control and development. Trends in Biochemical Sciences 36 633–641. (doi:10.1016/j.tibs.2011.09.001)
Karnik SK, Chen H, McLean GW, Heit JJ, Gu X, Zhang AY, Fontaine M, Yen MH & Kim SK 2007 Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. Science 318 806–809. (doi:10.1126/science.1146812)
Kim H, Lee JE, Cho EJ, Liu JO & Youn HD 2003 Menin, a tumor suppressor, represses JunD-mediated transcriptional activity by association with an mSin3A-histone deacetylase complex. Cancer Research 63 6135–6139.
Kitamura T 2013 The role of FOXO1 in beta-cell failure and type 2 diabetes mellitus. Nature Reviews Endocrinology 9 615–623. (doi:10.1038/nrendo.2013.157)
La P, Desmond A, Hou Z, Silva AC, Schnepp RW & Hua X 2006 Tumor suppressor menin: the essential role of nuclear localization signal domains in coordinating gene expression. Oncogene 25 3537–3546. (doi:10.1038/sj.onc.1209400)
Le Guezennec X, Vermeulen M, Brinkman AB, Hoeijmakers WA, Cohen A, Lasonder E & Stunnenberg HG 2006 MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties. Molecular and Cellular Biology 26 843–851. (doi:10.1128/MCB.26.3.843-851.2006)
Lewis PW, Elsaesser SJ, Noh KM, Stadler SC & Allis CD 2010 Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres. PNAS 107 14075–14080. (doi:10.1073/pnas.1008850107)
Li BE, Gan T, Meyerson M, Rabbitts TH & Ernst P 2013 Distinct pathways regulated by menin and by MLL1 in hematopoietic stem cells and developing B cells. Blood 122 2039–2046. (doi:10.1182/blood-2013-03-486647)
Li Y, Li W, Zhang JG, Li HY & Li YM 2014 Downregulation of tumor suppressor menin by miR-421 promotes proliferation and migration of neuroblastoma. Tumour Biology 35 10011–10017. (doi:10.1007/s13277-014-1921-1)
Lu J, Herrera PL, Carreira C, Bonnavion R, Seigne C, Calender A, Bertolino P & Zhang CX 2010 Alpha cell-specific Men1 ablation triggers the transdifferentiation of glucagon-expressing cells and insulinoma development. Gastroenterology 138 1954–1965. (doi:10.1053/j.gastro.2010.01.046)
Lu Y, Fei XQ, Yang SF, Xu BK & Li YY 2015 Glucose-induced microRNA-17 promotes pancreatic beta cell proliferation through down-regulation of Menin. European Review for Medical and Pharmacological Sciences 19 624–629.
Luzi E, Marini F, Giusti F, Galli G, Cavalli L & Brandi ML 2012 The negative feedback-loop between the oncomir Mir-24-1 and menin modulates the Men1 tumorigenesis by mimicking the ‘Knudson’s second hit’. PLoS ONE 7 e39767. (doi:10.1371/journal.pone.0039767)
MacConaill LE, Hughes CM, Rozenblatt-Rosen O, Nannepaga S & Meyerson M 2006 Phosphorylation of the menin tumor suppressor protein on serine 543 and serine 583. Molecular Cancer Research 4 793–801. (doi:10.1158/1541-7786.MCR-06-0123)
Marschalek R 2011 Mechanisms of leukemogenesis by MLL fusion proteins. British Journal of Haematology 152 141–154. (doi:10.1111/j.1365-2141.2010.08459.x)
Martinez SC, Cras-Meneur C, Bernal-Mizrachi E & Permutt MA 2006 Glucose regulates Foxo1 through insulin receptor signaling in the pancreatic islet beta-cell. Diabetes 55 1581–1591. (doi:10.2337/db05-0678)
Matkar S, Thiel A & Hua X 2013 Menin: a scaffold protein that controls gene expression and cell signaling. Trends in Biochemical Sciences 38 394–402. (doi:10.1016/j.tibs.2013.05.005)
Matsuzaki H, Daitoku H, Hatta M, Tanaka K & Fukamizu A 2003 Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. PNAS 100 11285–11290. (doi:10.1073/pnas.1934283100)
Meacham GC, Patterson C, Zhang W, Younger JM & Cyr DM 2001 The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nature Cell Biology 3 100–105. (doi:10.1038/35050509)
Meek DW 2015 Regulation of the p53 response and its relationship to cancer. Biochemical Journal 469 325–346. (doi:10.1042/BJ20150517)
Melchior F, Schergaut M & Pichler A 2003 SUMO: ligases, isopeptidases and nuclear pores. Trends in Biochemical Sciences 28 612–618. (doi:10.1016/j.tibs.2003.09.002)
Mensah-Osman E, Zavros Y & Merchant JL 2008 Somatostatin stimulates menin gene expression by inhibiting protein kinase A. American Journal of Physiology: Gastrointestinal and Liver Physiology 295 G843–G854. (doi:10.1152/ajpgi.00607.2007)
Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-Rosen O, Dou Y, Schnepp RW, Krankel C, Livolsi VA & Gibbs D et al. 2005 Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. PNAS 102 749–754. (doi:10.1073/pnas.0408836102)
Muhammad AB, Xing B, Liu C, Naji A, Ma X, Simmons RA & Hua X 2017 Menin and PRMT5 suppress GLP1 receptor transcript and PKA-mediated phosphorylation of FOXO1 and CREB. American Journal of Physiology: Endocrinology and Metabolism 313 E148–E166 . (doi:10.1152/ajpendo.00241.2016)
Nakata Y, Brignier AC, Jin S, Shen Y, Rudnick SI, Sugita M & Gewirtz AM 2010 c-Myb, Menin, GATA-3, and MLL form a dynamic transcription complex that plays a pivotal role in human T helper type 2 cell development. Blood 116 1280–1290. (doi:10.1182/blood-2009-05-223255)
Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Madhu B, Goldgraben MA, Caldwell ME & Allard D et al. 2009 Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324 1457–1461. (doi:10.1126/science.1171362)
Onodera A, Yamashita M, Endo Y, Kuwahara M, Tofukuji S, Hosokawa H, Kanai A, Suzuki Y & Nakayama T 2010 STAT6-mediated displacement of polycomb by trithorax complex establishes long-term maintenance of GATA3 expression in T helper type 2 cells. Journal of Experimental Medicine 207 2493–2506. (doi:10.1084/jem.20100760)
Orford K, Crockett C, Jensen JP, Weissman AM & Byers SW 1997 Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. Journal of Biological Chemistry 272 24735–24738. (doi:10.1074/jbc.272.40.24735)
Ouyang M, Su W, Xiao L, Rao JN, Jiang L, Li Y, Turner DJ, Gorospe M & Wang JY 2015 Modulation by miR-29b of intestinal epithelium homoeostasis through the repression of menin translation. Biochemical Journal 465 315–323. (doi:10.1042/BJ20141028)
Park KS, Martelotto LG, Peifer M, Sos ML, Karnezis AN, Mahjoub MR, Bernard K, Conklin JF, Szczepny A & Yuan J et al. 2011 A crucial requirement for Hedgehog signaling in small cell lung cancer. Nature Medicine 17 1504–1508. (doi:10.1038/nm.2473)
Rank G, Cerruti L, Simpson RJ, Moritz RL, Jane SM & Zhao Q 2010 Identification of a PRMT5-dependent repressor complex linked to silencing of human fetal globin gene expression. Blood 116 1585–1592. (doi:10.1182/blood-2009-10-251116)
Rea S, Eisenhaber F, O’Carroll D, Strahl BD, Sun ZW, Schmid M, Opravil S, Mechtler K, Ponting CP & Allis CD et al. 2000 Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406 593–599. (doi:10.1038/35020506)
Ribet D & Cossart P 2010 Post-translational modifications in host cells during bacterial infection. FEBS Letters 584 2748–2758. (doi:10.1016/j.febslet.2010.05.012)
Rulifson IC, Karnik SK, Heiser PW, ten Berge D, Chen H, Gu X, Taketo MM, Nusse R, Hebrok M & Kim SK 2007 Wnt signaling regulates pancreatic beta cell proliferation. PNAS 104 6247–6252. (doi:10.1073/pnas.0701509104)
Scacheri PC, Davis S, Odom DT, Crawford GE, Perkins S, Halawi MJ, Agarwal SK, Marx SJ, Spiegel AM & Meltzer PS et al. 2006 Genome-wide analysis of menin binding provides insights into MEN1 tumorigenesis. PLoS Genetics 2 e51. (doi:10.1371/journal.pgen.0020051)
Scoumanne A, Zhang J & Chen X 2009 PRMT5 is required for cell-cycle progression and p53 tumor suppressor function. Nucleic Acids Research 37 4965–4976. (doi:10.1093/nar/gkp516)
Shida T, Furuya M, Nikaido T, Hasegawa M, Koda K, Oda K, Miyazaki M, Kishimoto T, Nakatani Y & Ishikura H 2006 Sonic Hedgehog-Gli1 signaling pathway might become an effective therapeutic target in gastrointestinal neuroendocrine carcinomas. Cancer Biology and Therapy 5 1530–1538. (doi:10.4161/cbt.5.11.3458)
Slany RK 2005 When epigenetics kills: MLL fusion proteins in leukemia. Hematological Oncology 23 1–9. (doi:10.1002/hon.739)
Song TY, Lim J, Kim B, Han JW, Youn HD & Cho EJ 2014 The role of tumor suppressor menin in IL-6 regulation in mouse islet tumor cells. Biochemical and Biophysical Research Communications 451 308–313. (doi:10.1016/j.bbrc.2014.07.113)
Stehmeier P & Muller S 2009 Regulation of p53 family members by the ubiquitin-like SUMO system. DNA Repair 8 491–498. (doi:10.1016/j.dnarep.2009.01.002)
Stopa N, Krebs JE & Shechter D 2015 The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond. Cellular and Molecular Life Sciences 72 2041–2059. (doi:10.1007/s00018-015-1847-9)
Sundaresan S, Kang AJ, Hayes MM, Choi EK & Merchant JL 2017 Deletion of Men1 and somatostatin induces hypergastrinemia and gastric carcinoids. Gut 66 1012–1021. (doi:10.1136/gutjnl-2015-310928)
Tang J, Wu S, Liu H, Stratt R, Barak OG, Shiekhattar R, Picketts DJ & Yang X 2004 A novel transcription regulatory complex containing death domain-associated protein and the ATR-X syndrome protein. Journal of Biological Chemistry 279 20369–20377. (doi:10.1074/jbc.M401321200)
Theillaumas A, Blanc M, Couderc C, Poncet G, Bazzi W, Bernard C, Cordier-Bussat M, Scoazec JY & Roche C 2008 Relation between menin expression and NF-kappaB activity in an intestinal cell line. Molecular and Cellular Endocrinology 291 109–115. (doi:10.1016/j.mce.2008.05.019)
Thiel AT, Blessington P, Zou T, Feather D, Wu X, Yan J, Zhang H, Liu Z, Ernst P & Koretzky GA et al. 2010 MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell 17 148–159. (doi:10.1016/j.ccr.2009.12.034)
Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC, Chintagumpala M, Adesina A, Ashley DM & Kellie SJ et al. 2006 Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. Journal of Clinical Oncology 24 1924–1931. (doi:10.1200/JCO.2005.04.4974)
Tomizawa D, Koh K, Sato T, Kinukawa N, Morimoto A, Isoyama K, Kosaka Y, Oda T, Oda M & Hayashi Y et al. 2007 Outcome of risk-based therapy for infant acute lymphoblastic leukemia with or without an MLL gene rearrangement, with emphasis on late effects: a final report of two consecutive studies, MLL96 and MLL98, of the Japan Infant Leukemia Study Group. Leukemia 21 2258–2263. (doi:10.1038/sj.leu.2404903)
Tourkine N, Schindler C, Larose M & Houdebine LM 1995 Activation of STAT factors by prolactin, interferon-gamma, growth hormones, and a tyrosine phosphatase inhibitor in rabbit primary mammary epithelial cells. Journal of Biological Chemistry 270 20952–20961. (doi:10.1074/jbc.270.36.20952)
Tzivion G, Dobson M & Ramakrishnan G 2011 FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochimica et Biophysica Acta 1813 1938–1945. (doi:10.1016/j.bbamcr.2011.06.002)
van Nuland R, Smits AH, Pallaki P, Jansen PW, Vermeulen M & Timmers HT 2013 Quantitative dissection and stoichiometry determination of the human SET1/MLL histone methyltransferase complexes. Molecular and Cellular Biology 33 2067–2077. (doi:10.1128/MCB.01742-12)
Veniaminova NA, Hayes MM, Varney JM & Merchant JL 2012 Conditional deletion of menin results in antral G cell hyperplasia and hypergastrinemia. American Journal of Physiology: Gastrointestinal and Liver Physiology 303 G752–G764. (doi:10.1152/ajpgi.00109.2012)
Vijayaraghavan J, Maggi EC & Crabtree JS 2014 miR-24 regulates menin in the endocrine pancreas. American Journal of Physiology: Endocrinology and Metabolism 307 E84–E92. (doi:10.1152/ajpendo.00542.2013)
Vogt PK, Jiang H & Aoki M 2005 Triple layer control: phosphorylation, acetylation and ubiquitination of FOXO proteins. Cell Cycle 4 908–913. (doi:10.4161/cc.4.7.1796)
Waby JS, Bingle CD & Corfe BM 2008 Post-translational control of sp-family transcription factors. Current Genomics 9 301–311. (doi:10.2174/138920208785133244)
Wang Y, Ozawa A, Zaman S, Prasad NB, Chandrasekharappa SC, Agarwal SK & Marx SJ 2011 The tumor suppressor protein menin inhibits AKT activation by regulating its cellular localization. Cancer Research 71 371–382. (doi:10.1158/0008-5472.CAN-10-3221)
Wei H, Wang B, Miyagi M, She Y, Gopalan B, Huang DB, Ghosh G, Stark GR & Lu T 2013 PRMT5 dimethylates R30 of the p65 subunit to activate NF-kappaB. PNAS 110 13516–13521. (doi:10.1073/pnas.1311784110)
Wu X & Hua X 2008 Menin, histone h3 methyltransferases, and regulation of cell proliferation: current knowledge and perspective. Current Molecular Medicine 8 805–815. (doi:10.2174/156652408786733702)
Wu Y, Feng ZJ, Gao SB, Matkar S, Xu B, Duan HB, Lin X, Li SH, Hua X & Jin GH 2012 Interplay between menin and K-Ras in regulating lung adenocarcinoma. Journal of Biological Chemistry 287 40003–40011. (doi:10.1074/jbc.M112.382416)
Wu G, Yuan M, Shen S, Ma X, Fang J, Zhu L, Sun L, Liu Z, He X & Huang D et al. 2017 Menin enhances c-Myc-mediated transcription to promote cancer progression. Nature Communications 8 15278. (doi:10.1038/ncomms15278)
Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, Bonifas JM, Lam CW, Hynes M & Goddard A et al. 1998 Activating smoothened mutations in sporadic basal-cell carcinoma. Nature 391 90–92. (doi:10.1038/34201)
Yaguchi H, Ohkura N, Takahashi M, Nagamura Y, Kitabayashi I & Tsukada T 2004 Menin missense mutants associated with multiple endocrine neoplasia type 1 are rapidly degraded via the ubiquitin-proteasome pathway. Molecular and Cellular Biology 24 6569–6580. (doi:10.1128/MCB.24.15.6569-6580.2004)
Yang Y & Hua X 2007 In search of tumor suppressing functions of menin. Molecular and Cellular Endocrinology 265–266 34–41. (doi:10.1016/j.mce.2006.12.032)
Yang Y, Gurung B, Wu T, Wang H, Stoffers DA & Hua X 2010a Reversal of preexisting hyperglycemia in diabetic mice by acute deletion of the Men1 gene. PNAS 107 20358–20363. (doi:10.1073/pnas.1012257107)
Yang Y, Wang H & Hua X 2010b Deletion of the Men1 gene prevents streptozotocin-induced hyperglycemia in mice. Experimental Diabetes Research 2010 876701. (doi:10.1155/2010/876701)
Yang YJ, Song TY, Park J, Lee J, Lim J, Jang H, Kim YN, Yang JH, Song Y & Choi A et al. 2013 Menin mediates epigenetic regulation via histone H3 lysine 9 methylation. Cell Death and Disease 4 e583. (doi:10.1038/cddis.2013.98)
Yang JH, Chiou YY, Fu SL, Shih IY, Weng TH, Lin WJ & Lin CH 2014 Arginine methylation of hnRNPK negatively modulates apoptosis upon DNA damage through local regulation of phosphorylation. Nucleic Acids Research 42 9908–9924. (doi:10.1093/nar/gku705)
Yazgan O & Pfarr CM 2001 Differential binding of the Menin tumor suppressor protein to JunD isoforms. Cancer Research 61 916–920.
Yokobori T & Nishiyama M 2017 TGF-beta signaling in gastrointestinal cancers: progress in basic and clinical research. Journal of Clinical Medicine 6 11. (doi:10.3390/jcm6010011)
Yokoyama A & Cleary ML 2008 Menin critically links MLL proteins with LEDGF on cancer-associated target genes. Cancer Cell 14 36–46. (doi:10.1016/j.ccr.2008.05.003)
Yokoyama A, Wang Z, Wysocka J, Sanyal M, Aufiero DJ, Kitabayashi I, Herr W & Cleary ML 2004 Leukemia proto-oncoprotein MLL forms a SET1-like histone methyltransferase complex with menin to regulate Hox gene expression. Molecular and Cellular Biology 24 5639–5649. (doi:10.1128/MCB.24.13.5639-5649.2004)
Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M & Cleary ML 2005 The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis. Cell 123 207–218. (doi:10.1016/j.cell.2005.09.025)
Zhang H, Liu ZG & Hua XX 2011 Menin expression is regulated by transforming growth factor beta signaling in leukemia cells. Chinese Medical Journal 124 1556–1562.
Zhang H, Li W, Wang Q, Wang X, Li F, Zhang C, Wu L, Long H, Liu Y & Li X et al. 2012 Glucose-mediated repression of menin promotes pancreatic beta-cell proliferation. Endocrinology 153 602–611. (doi:10.1210/en.2011-1460)
Zhao Q, Rank G, Tan YT, Li H, Moritz RL, Simpson RJ, Cerruti L, Curtis DJ, Patel DJ & Allis CD et al. 2009 PRMT5-mediated methylation of histone H4R3 recruits DNMT3A, coupling histone and DNA methylation in gene silencing. Nature Structural and Molecular Biology 16 304–311. (doi:10.1038/nsmb.1568)